https://scholars.lib.ntu.edu.tw/handle/123456789/636693
標題: | IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study | 作者: | Kudo, Masatoshi Finn, Richard S Galle, Peter R Zhu, Andrew X Ducreux, Michel ANN-LII CHENG Ikeda, Masafumi Tsuchiya, Kaoru Aoki, Ken-Ichi Jia, Jing Lencioni, Riccardo |
關鍵字: | Atezolizumab; Barcelona Clinic Liver Cancer stage B; Bevacizumab; Unresectable hepatocellular carcinoma | 公開日期: | 八月-2023 | 卷: | 12 | 期: | 3 | 來源出版物: | Liver cancer | 摘要: | The phase III IMbrave150 study established atezolizumab + bevacizumab as standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis reports efficacy and safety results in patients with baseline Barcelona Clinic Liver Cancer (BCLC) stage B disease. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/636693 | ISSN: | 2235-1795 | DOI: | 10.1159/000528272 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。